SAKK 21/12: a phase II trial of transdermal CR1447 in breast cancer patients

OBJECTIVE: CR1447, a novel transdermal formulation of 4-hydroxytestosterone, has aromatase-inhibiting and androgen receptor (AR)-modulating properties (IC(50)4.4 nM) with antitumor effects against AR-positive tumor cells in vitro. This trial investigated the efficacy and safety of CR1447 for patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Vetter, Marcus, Rothgiesser, Karin M, Li, Qiyu, Hawle, Hanne, Schönfeld, Wolfgang, Ribi, Karin, Riniker, Salome, von Moos, Roger, Trojan, Andreas, Kralidis, Elena, Fehr, Mathias, Müller, Andreas, Thürlimann, Beat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259314/
https://www.ncbi.nlm.nih.gov/pubmed/37435469
http://dx.doi.org/10.1530/EO-21-0009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259314/
https://www.ncbi.nlm.nih.gov/pubmed/37435469
http://dx.doi.org/10.1530/EO-21-0009

Ejemplares similares